Ajanta Pharma Q2 net profit dips 7 to Rs 116 crore
Income from operations rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ajanta Pharma
KEY NOTE ADDRESS: Molecule to market
Dr Ramesh Jhawar, President of Ajanta Pharma, and a veteran with over four and half decades of experience in the life sciences…
Ajanta Pharma’s total comprehensive income dips by 23% in Q1 FY 2018
Company posted profit after tax at Rs. 95 crores
Ajanta Pharma receives US FDA approval for migraine drug
Zolmitriptan tablets are part of an 'ever-growing portfolio' that the company has developed for the US market
Ajanta Pharma has…
Ajanta Pharma posts Q4 and FY 2016 results
Revenue from operations grew 14 per cent at Rs 426 crores against Rs 372 crores in Q4 FY 2016
Ajanta Pharma gets US FDA nod for migraine pain relief drug
Ajanta Pharma USA is scheduled to launch the almotriptan malate tablets in the US shortly
Ajanta Pharma has received final…
Ajanta Pharma Q3 net up 20 per cent at Rs 111.3 crore
Net sales of the company rose to Rs 465.71 crore for the December quarter
Ajanta Pharma has reported a 19.60 per cent increase in…
Ajanta Pharma launches montelukast IR and montelukast chewable tablets
US FDA has approved montelukast offerings in three dosage forms viz immediate-release tablets, chewable tablets, and oral granules…
Ajanta Pharma posts Rs 438 crore consolidated revenue in Q2 of FY 2015-16
EBITDA growth was at Rs 154 crore
Ajanta Pharma has reported its performance for the second quarter and half year ended September…
Ajanta Pharma bags recognition from Fortune India
The company has been ranked as the third largest wealth creator
Ajanta Pharma has been ranked as the third largest wealth creator…